Circulating tumor DNA to guide diagnosis and treatment of localized and locally advanced non-small cell lung cancer

A Marinello, M Tagliamento, A Pagliaro, N Conci… - Cancer Treatment …, 2024 - Elsevier
Liquid biopsy is a minimally invasive method for biomarkers detection in body fluids,
particularly in blood, which offers an elevated and growing number of clinical applications in …

Prognostic value of 18F-fluorodeoxyglucose PET/computed tomography in non–small-cell lung Cancer

G Cheng, H Huang - PET clinics, 2018 - pet.theclinics.com
Lung cancer remains a leading cause of cancerrelated deaths worldwide, accounting for
approximately 224,390 new patients and 158,080 deaths in 2016, according to the …

A novel [89Zr]-anti-PD-1-PET-CT to assess response to PD-1/PD-L1 blockade in lung cancer

A Puyalto, M Rodríguez-Remírez, I López… - Frontiers in …, 2023 - frontiersin.org
Background Harnessing the anti-tumor immune system response by targeting the program
cell death protein (PD-1) and program cell death ligand protein (PD-L1) axis has been a …

Radiotherapy response evaluation using FDG PET-CT—established and emerging applications

H Cliffe, C Patel, R Prestwich… - The British journal of …, 2017 - academic.oup.com
Radiation therapy is a common component of curative cancer treatment. However, there is a
significant incidence of treatment failure. In these cases, salvage surgical options are …

18F-FDG PET/CT in restaging and evaluation of response to therapy in lung cancer: state of the art

A Castello, S Rossi, E Lopci - Current Radiopharmaceuticals, 2020 - ingentaconnect.com
Background: Metabolic information provided by 18F-FDG PET/CT are useful for initial
staging, therapy planning, response evaluation, and to a lesser extent for the follow-up of …

PET-CT in the UK: current status and future directions

AF Scarsbrook, SF Barrington - Clinical radiology, 2016 - Elsevier
Combined positron-emission tomography and computed tomography (PET-CT) has taken
the oncological world by storm since being introduced into the clinical domain in the early 21 …

Is multidisciplinary management possible in the treatment of lung cancer? A report from three Italian meetings

D Franceschini, A Bruni, P Borghetti, N Giaj-Levra… - La radiologia …, 2020 - Springer
Purpose To report criticisms and barriers to the “real-life” application of international
guidelines and recent developments in the management of locally advanced non-small cell …

18F-FDG PET/CT for response assessment in lung cancer

C Marcus, SH Tajmir, SP Rowe, S Sheikhbahaei… - Seminars in Nuclear …, 2022 - Elsevier
Treatment response assessment in lung cancer is crucial in the management strategy and
outcome of patients. Accurate treatment response assessment can guide the treating …

[HTML][HTML] Evaluation of tumor response after stereotactic body radiation therapy for lung cancer: Role of 18F-fluorodeoxyglucose positron emission tomography …

P Alcantara, BC Martínez… - Journal of Clinical …, 2020 - ncbi.nlm.nih.gov
Background: Early identification of patients who fail to lung stereotactic body radiation
therapy (SBRT) is vital as they can benefit from salvage therapy. Main guidelines …

KRAS mutation status is not a predictor for tumor response and survival in rectal cancer patients who received preoperative radiotherapy with 5-fluoropyrimidine …

JW Lee, JH Lee, BY Shim, SH Kim, MJ Chung, BH Kye… - Medicine, 2015 - journals.lww.com
We evaluated the tumor response and survival according to the KRAS oncogene status in
locally advanced rectal cancer. One hundred patients with locally advanced rectal cancer …